Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00001220
Other study ID # 870160
Secondary ID 87-CC-0160
Status Completed
Phase N/A
First received November 3, 1999
Last updated March 3, 2008
Start date October 1987
Est. completion date November 2005

Study information

Verified date November 2005
Source National Institutes of Health Clinical Center (CC)
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Observational

Clinical Trial Summary

This study will identify clinical signs and symptoms critical for diagnosing swallowing disorders and will characterize swallowing problems in various patient populations, such as patients with Parkinson's disease, stroke, post-polio syndrome, multiple sclerosis and other conditions that cause swallowing abnormalities.

Patients with swallowing difficulties who are enrolled in NIH neurology or speech pathology protocols may be eligible for this study. Participants will undergo the following procedures:

1. Oral examination-A neurologist and speech pathologist examine the patient's swallowing function. The patient is interviewed about difficulties with food intake, chewing and swallowing during meals.

2. Ultrasound examination-Ultrasound creates image of areas inside the body using sound waves. With the patient in a sitting position, a 3/4-inch transducer (device for transmitting and receiving sound waves) is placed under the chin to visualize tongue movements during swallowing.

3. Modified barium swallow-While standing or sitting, the patient swallows 1/2 teaspoon of flavored barium (a radioactive substance) six times (a total of 3 teaspoons), while the tongue and pharynx (tube leading from the mouth to the esophagus) are scanned and videotaped. The barium is given in three consistencies-thin, medium and thick (pudding-like).

4. Electromyography-A small plastic strip with wires attached is placed under the patient's chin. The patient then swallows 1/2 ounce of barium three times in a row, and the movement of the chin muscles during swallowing is displayed. Patients may also be asked to swallow 5/8 cup of barium twice; once with the head tilted upward and once with the head untilted.

Depending on the test results, patients may be asked to return for follow-up study and monitoring.


Description:

Patients with neurological or neuromuscular conditions may be silent aspirators or at risk for laryngeal penetration or aspiration because of abnormal oropharyngeal functioning and thus are at risk for aspiration pneumonia and its serious effects. By providing identification of the components of the abnormal swallow, and comparing swallowing across tasks, we may avoid aspiration and can instruct patients on preventative or compensatory swallowing techniques.

We will study the oral, pharyngeal and upper esophageal phases of swallow using both ultrasonic imaging and videofluoroscopy in patients with neurologic, genetic, systemic, and neuromuscular conditions. Most of the previous studies of swallowing have utilized only one diagnostic imaging technique and have thus provided an incomplete swallowing assessment as each procedure has unique, but limited capabilities for visualizing the anatomy and physiology of the swallow.

We also plan to compare discrete and continuous swallowing in these populations. While the motor physiology for discrete swallowing (i.e., single swallow) has been well studied, little is known about the details of oral, laryngeal, and pharyngeal coordination during sequential swallowing as a part of continuous drinking--a common event in everyday eating. A portion of the protocol will study the effects of fast-paced movement sequencing on the coordination of the tongue, velum, larynx, and pharynx during continuous drinking. Videofluoroscopy and ultrasound may be paired or used individually to collect data from normal subjects and patients with known dysphagia while they perform sequential and discrete swallowing tasks. A number of timing and displacement measurements of the structures activated during these tasks will be made from the digitized video images of each swallow, and analyses will be carried out subsequently across tasks and subjects.


Recruitment information / eligibility

Status Completed
Enrollment 750
Est. completion date November 2005
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility INCLUSION CRITERIA:

Any Clinical Center inpatients and outpatients with known or suspected dysphagia on any other NIH institute protocol can be included for study as well as patients who are admitted specifically for this protocol.

Those patients at risk for oropharyngeal dysfunction will be screened initially by completing a self-assessment swallowing questionnaire, and by an interview with staff and/or family members. Patients who demonstrate appropriate signs and symptoms of dysphagia and oral motor impairment on the screening assessment will be considered for the protocol:

Difficulty swallowing food or pills.

Changed swallowing ability.

Coughing or choking when eating.

Shortness of breath during swallowing.

Food backing up into the mouth or nasal passage.

Fever or voice changes after swallowing.

Pain when swallowing.

Unexplained loss of weight.

EXCLUSION CRITERIA:

Patients who are severely demented or severely compromised will be excluded if they do not have sufficient cognitive ability to follow directions.

Patients who are non-ambulatory will be excluded if they can not be braced or supported within the fluoroscopy unit.

Highly agitated individuals will also be excluded if they are unable to remain confined in the equipment.

Infants and children under age 3 will be excluded due to radiation risk on the developing visual system.

Study Design

N/A


Locations

Country Name City State
United States National Institutes of Health Clinical Center (CC) Bethesda Maryland

Sponsors (1)

Lead Sponsor Collaborator
National Institutes of Health Clinical Center (CC)

Country where clinical trial is conducted

United States, 

References & Publications (3)

Donner MW. Swallowing mechanism and neuromuscular disorders. Semin Roentgenol. 1974 Oct;9(4):273-82. — View Citation

Litvan I, Sastry N, Sonies BC. Characterizing swallowing abnormalities in progressive supranuclear palsy. Neurology. 1997 Jun;48(6):1654-62. — View Citation

Sonies BC, Parent LJ, Morrish K, Baum BJ. Durational aspects of the oral-pharyngeal phase of swallow in normal adults. Dysphagia. 1988;3(1):1-10. Review. — View Citation

See also
  Status Clinical Trial Phase
Terminated NCT04579666 - MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS) Phase 2
Completed NCT03706391 - Study of ALS Reversals 4: LifeTime Exposures
Active, not recruiting NCT03067857 - Autologous Bone Marrow-Derived Stem Cell Therapy for Motor Neuron Disease Phase 1/Phase 2
Completed NCT02464748 - Telehealth in Motor Neurone Disease N/A
Completed NCT00956488 - Supported Treadmill Ambulation Training (STAT) for Patients Diagnosed With Amyotrophic Lateral Aclerosis Phase 1/Phase 2
Terminated NCT00537446 - Effect of Noninvasive Ventilation on Lung Function in Amyotrophic Lateral Sclerosis N/A
Recruiting NCT04944940 - Clinical, Molecular and Imaging Biomarkers in Spinal and Bulbar Muscular Atrophy (SBMA)
Recruiting NCT03362658 - Novel MRI Biomarkers for Monitoring Disease Progression in ALS
Completed NCT00714636 - Cerebrospinal Fluid Repository N/A
Completed NCT00071435 - Brain Function in Primary Lateral Sclerosis N/A
Completed NCT00076687 - Safety Study of Botulinum Toxin Type A in Post-Upper Limb Stroke Patients With Reduced Lung Function Phase 2
Completed NCT03487263 - Dose-Escalation, Safety and Pharmacokinetic Study of IC14 in Motor Neurone Disease Phase 1
Enrolling by invitation NCT05725759 - Rehabilitation in SOD1 ALS Treated With Tofersen
Active, not recruiting NCT03811301 - [BrainConnexion] - Neurodevice Phase I Trial N/A
Completed NCT02469896 - A Trial of Tocilizumab in ALS Subjects Phase 2
Completed NCT02011204 - Study of Electrical Impedance Myography (EIM) in ALS N/A
Completed NCT01495390 - A Longitudinal Study of Amyotrophic Lateral Sclerosis (ALS) Biomarkers N/A
Completed NCT02870634 - Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND Phase 1
Recruiting NCT06201650 - Neurofilament Light Chain in Amyotrophic Lateral Sclerosis
Active, not recruiting NCT04240925 - Tolerability, Safety and Efficacy of Sigh Breaths During NIMV in Motor Neuron Disease N/A